HPV阳性与阴性口咽鳞癌颈部淋巴结转移分布比较
p16阳性组cN+和pN+率均显著更高,但淋巴结引流分布无实质性差异,提示两组颈部治疗范围不应区别对待。
要点
- p16阳性口咽鳞癌患者cN+率88.3%、pN+率91.2%,均显著高于p16阴性患者。
- 临床淋巴结分布上,p16阳性患者同侧IV区阳性更多,对侧III和IV区阳性更少。
- 病理淋巴结分布上,cN0患者两组各颈区无显著差异,cN+患者也无差异。
核心结论
- p16阳性口咽鳞癌患者临床和病理淋巴结阳性率均显著高于p16阴性患者。
- 但两组间淋巴结引流分布无实质性差异,颈部治疗范围不应因p16状态而不同。
研究设计与样本
- p16阴性组126例,p16阳性组137例,HPV状态通过p16免疫组化评估。
- 排除既往头颈癌、既往颈部手术、诱导化疗或原发灶不明癌患者。
主要发现
- p16阴性和p16阳性组cN+率分别为54%和88.3%(p < 0.001),pN+率分别为61.9%和91.2%(p < 0.001)。
- 临床淋巴结分布:p16阳性患者同侧IV区阳性更多(p = 0.003),对侧III和IV区阳性更少(p = 0.003和p = 0.045)。
- 病理淋巴结分布:cN0患者中p16阴性与阳性组各颈区无显著差异(p = 0.33至1)。
- cN+患者中,p16阴性与阳性组同侧Ib、II、III、IV、V区分布无差异。
- 对侧颈p16阴性患者转移主要见于II、III、IV区,p16阳性患者仅见于II区(p = 0.03)。
关键数值与推荐
- p16阴性组cN+率54%,p16阳性组88.3%(p < 0.001)。
- p16阴性组pN+率61.9%,p16阳性组91.2%(p < 0.001)。
- 临床同侧IV区阳性p16阳性更多(p = 0.003),对侧III区(p = 0.003)和IV区(p = 0.045)阳性p16阳性更少。
- 对侧颈p16阴性患者转移主要位于II、III、IV区,p16阳性仅位于II区(p = 0.03)。
临床怎么用
- p16阳性口咽鳞癌患者颈部淋巴结阳性率更高,分期评估时应关注。
- 尽管阳性率不同,p16状态不应作为缩小颈部治疗范围的依据。
- 对侧颈区预防照射范围可参考p16状态下的分布特征,但需个体化决策。
局限性
- 回顾性研究,可能存在选择偏倚。
- 仅纳入接受颈淋巴结清扫的患者,未反映未手术患者情况。
- 样本来自3家法国机构,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In oropharyngeal squamous cell carcinoma (OP-SCC), the prevalence and distribution of clinical and pathological lymph node metastasis in the neck have been extensively reported. It served as the basis for consensus recommendations on the selection of the lymph node levels in the neck requiring a treatment. The objective of the study is to compare the prevalence and distribution of neck node metastases in HPV+ and HPV- OP-SCC from a large series of patients with OP-SCC who underwent a cervical lymph-node dissection (LND) as part of their treatment. METHODS: The study concentrated on OP-SCC patients treated by various neck node dissection (LND) procedures from January 2014 to December 2018 in 3 French institutions. Patients with prior head and neck cancer, prior neck surgery, the use of induction chemotherapy, or patients with carcinoma of unknown primary were excluded. HPV-status was assessed by p16 immunohistochemistry. For each patient, the clinical and the pathological nodal status, as well as the distribution of the positive nodes in each neck level (from Ia to V) were reported. RESULTS: Two-hundred and sixty-three patients were included (126 p16-negative (p16-), and 137 p16-positive (p16+). The rate of clinical positive node (cN+) reached 54% and 88.3% in the p16- and p16+ groups, respectively (p < 0.001); the corresponding rate of pathological positive node (pN+) reached 61.9% and 91.2%, respectively (p < 0.001). Regarding the clinical lymph node distribution, in p16+ patients, more positive nodes were observed in the ipsilateral level IV (p = 0.003), and less positive nodes were observed in the contralateral levels III and IV (p = 0.003 and p = 0.045, respectively). Regarding the pathologic lymph node distribution in the ipsilateral neck, in the cN0 patients, no significant difference was observed between p16- and p16+ patients (p = 0.33 to 1); in the cN+ patients, the nodes were distributed in levels Ib, II, III, IV and V without differences between the p16- and the p16+ patients. In the contralateral neck of p16- patients, nodes metastases were mainly observed in levels II, III and IV, whereas for the p16+ patients, positive nodes were only observed in level II (p = 0.03). CONCLUSION: This study demonstrated the higher prevalence of cN+ and pN+ in p16+ OP-SCC patients, but without meaningful difference in the distribution of the lymph node drainage between p16- and p16+ OP-SCC. It indicates that no difference should be made between p16- and p16+ patients regarding the extend of neck treatment.
引用
- Bauwens L, Baltres A, Fiani DJ, et al. Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiother Oncol. 2021. PMID: 33545255. doi:10.1016/j.radonc.2021.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。